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Vitamin D and Cardiovascular Disease
Will It Live Up to its Hype?
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Substantial evidence suggests that a large portion of the population have suboptimal levels of vitamin D, which may
adversely affect the cardiovascular (CV) system, including increasing levels of parathyroid hormone, activating the
renin-angiotensin-aldosterone system, and increasing insulin resistance, thus leading to hypertension and left ventric-
ular hypertrophy, metabolic syndrome/diabetes mellitus, systemic inflammation, and increased risk of atherosclero-
sis and CV disease events. We review the evidence that vitamin D deficiency is associated with incident CV disease
events, as well as evidence that vitamin D supplementation is associated with reduction in CV diseases. Although the
current evidence has created substantial hype, randomized controlled trials are needed to determine whether routine
vitamin D assessment and supplementation will improve CV outcomes. (J Am Coll Cardiol 2011;58:1547–56)
© 2011 by the American College of Cardiology Foundation
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fDeficiency of vitamin D is now recognized to be highly
prevalent in the U.S. and worldwide, impacting between
30% and 50% of the general population (1,2). The Institute
of Medicine (IOM) has suggested, however, that the
prevalence of vitamin D deficiency may be overestimated in
North America, and indicates that roughly one-quarter of
the U.S. population have inadequate vitamin D levels, 8%
are at risk of deficiency, and 1% have vitamin D levels that
may be too high and potentially harmful (3). Traditionally,
the most characterized consequence of vitamin D deficiency
has involved the musculoskeletal system, leading to rickets
in children and osteomalacia and osteoporosis in adults.
However, it is now recognized that vitamin D receptors are
present on a large variety of cell types, including osteoblasts,
immunologic cells, nerve cells, pancreatic beta cells, vascular
endothelial cells, and possibly myocytes and cardiac muscle
cells (1,4) (as the presence of vitamin D receptors on
cardiac, skeletal, and smooth muscle cells has recently been
questioned) (5). A growing body of evidence indicates that
low levels of vitamin D may adversely affect both the risk of
colorectal cancer and numerous cardiovascular (CV) dis-
eases, and therefore impact total survival (1,2,5–7).
This state-of-the-art review, therefore, focuses on the
relationship between vitamin D and CV and metabolic risk
factors and CV disease events, as well as on the potential
role of vitamin D repletion to reduce these events and
prevent the development and progression of CV diseases.
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accepted July 5, 2011.The ABCs of Vitamin D
There are 2 major forms of vitamin D, vitamin D2 (ergo-
calciferol) and vitamin D3 (cholecalciferol). Vitamin D2 is
ound in plants and can be consumed in fortified foods or as
supplement; in plants, it is the product of ultraviolet B
UVB) (290 mm to 315 mm) irradiation of ergosterol.
itamin D3 is obtained from either dietary sources or
through conversion of 7-dehydrocholesterol in the skin
upon exposure to UVB radiation (1,4). Dietary sources of
vitamin D are limited to fatty fish (wild or farm salmon,
mackerel, tuna fish, sardines, and cod liver oil) and products
fortified with vitamin D—depending on the country, these
may include diary products, cereals, margarine, flour, and
orange juice (8,9).
Both vitamin D3 obtained from exposure to the sun and
from dietary sources are hydroxylated in the liver to 25-
hydroxy vitamin D (25[OH]D), which is then converted to
the active form of vitamin D, 1,25-dihydroxy vitamin D
(1,25[OH]2D) by 1-alpha-hydroxylase in the kidney
1,2,4). Although vitamin D has been classified as a vitamin
or decades, clearly the 1,25(OH)2D functions as a hor-
mone, since it is produced predominantly by 1 organ (the
kidneys, although both vascular smooth muscle and endo-
thelial cells may also be able to convert 25[OH]D to
1,25[OH]2D) and then exerts wide-range effects on numer-
ous organs, including the CV system (10). Although
1,25(OH)2D is considered to be the active form of vitamin
D, its levels in the serum do not correlate with overall
vitamin D status, whereas level of 25(OH)D is the marker
that is more clinically relevant (8).
The circulating hormone 1,25(OH)2D crosses the cell
embrane and cytoplasm and reaches the nucleus of the
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tors, which in turn binds to reti-
noic acid receptors and serves as
a nuclear transcription factor, in-
ducing protein synthesis and al-
tering genetic function (4). Vita-
min D directly or indirectly
regulates numerous genes, in-
cluding those involved in renin
production in the kidney, insulin
production by beta cells in the
pancreas, and growth and prolif-
eration of vascular smooth mus-
cle cells and cardiac muscle cells,
as well as functions of lympho-
cytes and macrophages, many of
which may be involved in the
pathogenesis and progression of
CV diseases.
Vitamin D Deficiency
Vitamin D deficiency is a com-
mon problem in the United
States and worldwide (1,2). Optimal levels of 25(OH)D are
not firmly established, but a level 75 nmol/l (30 ng/ml)
has been suggested to be a threshold below which condition
such as falls, fractures, and even colorectal cancers are
increased (5). Potential cutpoints for defining vitamin D
status are listed in Table 1, including the IOM’s definitions
of risk of deficiency, risk of inadequacy, adequacy, and risk
of concern (including the fact that there may be a “U-shaped”
relationship where very high levels may be detrimental,
including increasing certain cancers, especially pancreatic
cancer [7], fractures and falls, as well as CV risk and
all-cause mortality, which is discussed in the following text).
Data from the Third National Health and Nutrition Survey
(NHANES III) indicate that approximately 5% of persons
Abbreviations
and Acronyms
25(OH)D  25-
hyroxyvitamin D
1,25(OH)2D  1,25
dihydroxyvitamin D
CHD  coronary heart
disease
CKD  chronic kidney
disease
CRP  C-reactive protein
CV  cardiovascular
IOM  Institute of
Medicine
MetS  metabolic
syndrome
PTH  parathyroid hormone
RAAS  renin-angiotensin-
aldosterone system
T2DM  type 2 diabetes
mellitus
UVB  ultraviolet B
Current Vitamin D Status DefinitionsTable 1 Current Vitamin D Status Definitions
Serum 25-Hydroxyvitamin D, ng/ml Vitamin D Status
10 Severe deficiency
10–20 Deficiency
20–30 Mild-moderate deficiency
30 Sufficient
40–50 Ideal
50–150 Indeterminate data*
150 Toxicity
Institute of Medicine Definitions†
12 At risk of deficiency
12–19 At risk of inadequacy
20–50 Sufficient
50 Possibly harmful*Some data suggest increased falls, fractures, certain cancers, and even cardiovascular risk at
values 50 ng/ml. †Definitions adapted from Looker et al. (3).in the United States have levels 25 nmol/l (10 ng/ml) and
close to 60% have levels 62.5 nmol/l (25 ng/ml) (11).
The prevalence of vitamin D deficiency increases with
greater distance from the equator because of increased
atmospheric filtering of the UVB radiation. Additionally,
ethnic groups with darker skin (e.g., African Americans)
require considerably more sun exposure to synthesize ade-
quate amounts of vitamin D compared with lighter skin
persons (12). Considering the concerns about various skin
cancers over recent decades, the use of sunscreen and
sun-avoiding strategies has also led to dramatic reductions
in vitamin D cutaneous production. That, coupled with
increasingly sedentary, indoor lifestyles has further added to
a higher prevalence of vitamin D deficiency. Obesity has
also increased at epidemic proportions in the United States
and most Westernized cultures, and may lead to reduced
vitamin D bioavailability because of vitamin D being se-
questered in the excess adipose tissue (13). The exact
explanation for the lower levels of vitamin D in obesity,
however, is not clearly established, as vitamin D levels have
been inversely related with visceral fat but less so with
subcutaneous fat (14). Clearly, however, obese persons
appear to have a poorer response to supplementation or
UVB light compared to lean persons (15). The elderly also
have reduced capacity for UVB-induced vitamin D synthe-
sis in the skin, and are particularly susceptible to vitamin D
deficiency (1,2,16,17). Common causes of vitamin D defi-
ciency, including recently identified genetic factors (18), are
listed in Table 2.
Vitamin D and CV Risk Factors
There is increasing evidence that vitamin D plays a role in
determining risk for various cardiometabolic outcomes,
Major Risk Factors for Vitamin D DeficiencyTable 2 Major Risk Factors for Vitamin D Deficiency
Aging
Increased distance from the equator
Winter seasons
Darkly pigmented skin
Institutionalized/housebound
Sunscreens and cover-up clothing
Air pollution
Smoking
Obesity
Physical inactivity
Genetic factors
Malabsorption
Renal disease
Liver disease
Certain medications
Glucocorticoids
Antirejection medications
Human immunodeficiency virus medications
Certain antiepileptic drugsparticularly metabolic syndrome (MetS) and type 2 diabetes
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idemiological studies also suggest that the rate of hyperten-
sion, T2DM, and coronary heart disease (CHD) increase in
proportion to increasing distance from the equator, suggest-
ing a potential link to the vitamin D mechanism.
Hypertension. The renin-angiotensin-aldosterone system
(RAAS) clearly plays a major role in the pathogenesis of
CV diseases (1,2,10,20). Vitamin D exerts a role in
regulating the RAAS, and vitamin D deficiency predis-
poses to up-regulation of the RAAS and hypertrophy of
both smooth muscle cells and the left ventricle (and left
ventricular hypertrophy is a known risk factor or marker
of CV disease risk) (10,21,22). In humans, 1,25(OH)2D
nhibits the RAAS and may lower blood pressure; in fact,
tanning study demonstrated that UVB radiation from
anning 3 times a week for 3 months led to a nearly 200%
ncrease in 25(OH)D levels and a 6 mm Hg decrease in
oth systolic and diastolic blood pressure (23). Vitamin D
lso impacts endothelial cell function, regulating endo-
helial cell-dependent vasodilation (24–26). A small
tudy of patients with T2DM and low baseline 25(OH)D
evels demonstrated that a single dose of 100,000 IU
itamin D2 reduced systolic blood pressure by 14 mm Hg
and improved endothelial function as assessed by forearm
blood flow (24). In the NHANES III study, the average
systolic blood pressure was nearly 3 mm Hg lower in
subjects with the highest quartile of 25(OH)D compared
to subjects in the lowest quartile (27). However, in a
recent meta-analysis of 3 cohorts, lower 25(OH)D was
associated with an 80% greater risk of incident hyperten-
sion, whereas in a meta-analysis of 10 trials, supplemen-
tation with vitamin D only nonsignificantly reduced
systolic blood pressure by 2 mm Hg and did not reduce
diastolic blood pressure (19).
Type 2 diabetes mellitus. Vitamin D also affects mech-
anisms related with MetS and T2DM pathophysiology,
including impaired B-cell function and insulin resistance,
potentially by directly activating vitamin D receptors or
by indirect effects by a calcium homeostasis regulation
(19,28). A study of 10,000 Finnish children who were
given 2,000 IU vitamin D3 per day during the first year of
ife demonstrated a 78% reduced risk of type 1 diabetes
ver a 30-year follow-up (29). Subsequently, this finding
as confirmed by a meta-analysis of 5 observational
tudies in England (30). One study reported that a daily
ntake of 800 IU of vitamin D compared with 400 IU
f vitamin D reduced the risk of T2DM by nearly
ne-third (31). In a 6-month study of 81 South Asian
omen with insulin resistance, 1,000 IU daily of vitamin D
educed insulin resistance and improved insulin sensitivity,
educing fasting insulin levels without changing insulin
ecretion (32). However, in a recent major review by Pittas
t al. (19) of 13 observational studies (14 cohorts) and 18
rials, 3 of 6 analyzed from 4 different cohorts, reported a
ower incident T2DM in the highest versus the lowest
itamin D status group, and 8 trials found no effect of ditamin D supplementation on glycemia or incident
2DM. Although the reasons for these inconsistencies in
oth the hypertension and T2DM trials are uncertain,
otential explanations include baseline 25(OH)D levels,
arious vitamin D doses, achieved 25(OH)D levels, and
arious study designs (including primary, secondary, and
ertiary prevention trials).
yperparathyroidism. Chronic vitamin D deficiency
auses secondary hyperparathyroidism, which may mediate
evere detrimental CV effects (1). Vitamin D deficiency
educes intestinal calcium absorption by 50%, and the
eduction in serum calcium triggers release of parathyroid
ormone (PTH), which corrects serum calcium by promot-
ng mobilization of calcium from bone, increasing reabsorp-
ion of calcium from renal tubules, and stimulating in-
reased production of 1,25(OH)2D from the kidney (1,4).
The threshold for elevation of PTH is a 25(OH)D level
30 ng/ml, with particular increases in PTH levels at
25(OH)D levels 16 ng/ml (10).
It appears that both primary and secondary hyperpara-
thyroidism is associated with increased risk of CV diseases.
Elevated levels of PTH are associated with increases in
arterial pressure and myocardial contractility, which can lead
to apoptosis, fibrosis, and vascular smooth muscle cell
hypertrophy as well as left ventricular hypertrophy (10,33).
Vitamin D deficiency and increased PTH also predisposes
to mitral annular calcification, valvular sclerosis/calcification,
and even calcification of the myocardium (1,34). Chronic
kidney disease (CKD) is certainly associated with increased
CV risk. The link between CKD and hyperparathyroid-
ism is demonstrated in a study of patients with advanced
CKD, in which patients with PTH levels 250 pg/ml
had doubling of CV risk compared to patients with PTH
250 pg/ml (35). Elevated levels of PTH in the elderly
have also been associated with a nearly 2-fold increase in
mortality (36).
Inflammation. Substantial evidence indicates that athero-
sclerosis is an inflammatory disease and that inflammation
plays a role in major CV disease events, and efforts to reduce
inflammation may be warranted (37–39). Low 25(OH)D
and increases in PTH levels increase the risk of inflamma-
tion, as documented by elevated levels of C-reactive protein
and interleukin-10 (10). Administration of 1,25(OH)2D in
he setting of vitamin D deficiency has been shown to
own-regulate inflammatory biomarkers such as C-reactive
rotein (40).
epression. Depression is one of the leading causes of
isability in the United States, and is a known CV risk
actor that is also related with recovery after major CV
isease events (41–43). Recently, vitamin D has been
mplicated as a factor affecting cognitive function and
ental health (44,45). In fact, vitamin D concentrations
ave been found to be low in patients with mood disorders,
ncluding depression (46,47). In data from the NHANES
II study, in nearly 8,000 noninstitutionalized U.S. resi-
ents, the likelihood of having depression was significantly
(
r
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wise, among a CV disease population of 7,000 patients
50 years of age with no history of depression, low vitamin
D levels were shown to be a associated with incident
depression (47). It is known that vitamin D receptors are
present in the brain, and enzymes are present in the central
nervous system that are involved in vitamin D hydroxylation
(48,49). Additionally, elevated levels of PTH due to vitamin
D deficiency may also play a role in the development of
depression (50,51). However, at present, the potential link
between vitamin D status, depression, and CV diseases
seems to be intriguing but speculative at best.
Vitamin D, cardiovascular disease, and mortality. There
are several mechanisms by which vitamin D may be
associated with atherosclerosis and CV disease events
(Fig. 1) (1,2), and numerous recent studies have found
high rates of CV diseases among patients with lower
levels of vitamin D. In 1,739 Framingham Offspring
Study participants who were free of CV disease at
baseline, the rate of major CV disease events was 53% to
80% higher among those with low vitamin D levels, with
the increased risk magnified among those with hyperten-
sion (Fig. 2) (52). However, this study suggested a
slightly increased risk at higher 25(OH)D levels. In an
analysis of 13,331 adults from the NHANES III study
followed up for a median of 8.7 years, mortality was
inversely associated with vitamin D levels, with the
lowest quartile of 25(OH)D (17.8 ng/ml) having a 26%
increased mortality compared with the highest quartile (Fig. 3)
53). The NHANES III study also suggested a U-shaped
elationship for 25(OH)D, with a slight increased mortality
Figure 1 Potential Mechanisms for CV Effects of Vitamin D De
CV  cardiovascular; DM  diabetes mellitus; HTN  hypertension; LVH  left ve
RAAS  renin-angiotensin-aldosterone system.noted at high (50 ng/ml) levels. In a prospective study of
3,258 consecutive patients scheduled for coronary angiog-
raphy, low 25(OH)D and 1,25(OH)2D levels were indepen-
dently associated with all-cause and CV mortality (Fig. 4) (54).
In an analysis of 27,000 patients from the Inter-
mountain Healthcare System, the prevalence of vitamin
D deficiency (30 ng/ml) was 60%; and vitamin D
deficiency was associated with highly significant (p 
0.0001) increases in the prevalence of T2DM, hyperten-
sion, and dyslipidemia. Moreover, vitamin D deficiency
was highly associated with CHD, myocardial infarction,
heart failure, and stroke, as well as total mortality (Fig. 5)
(55). In a 10-year follow-up of 18,225 men in the Health
Professionals Follow-up Study, low levels of 25(OH)D
were associated with higher risk of myocardial infarction,
even after controlling for other CHD risk factors (56). A
recently published multicenter study evaluating patients
admitted with acute coronary syndromes found that 96%
of these patients had abnormal 25(OH)D levels 30
ng/ml (57).
Although there are now many studies suggesting
higher CV risk associated with low vitamin D levels, the
data for routine vitamin D supplementation are more
sparse (18). Autier and Gandini (58) analyzed 18 inde-
pendent randomized controlled trials of 57,000 partic-
ipants (with 4,700 deaths during a mean follow-up of
5.7 years). Although there was considerably variability in
these trials, as well as the dose of vitamin D administra-
tion (from 300 IU to 2,000 IU daily), the summary
relative risk for all-cause mortality was reduced by 7%
with vitamin D therapy (Fig. 6) (58). Another meta-
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statistically nonsignificant, 10% reduction in CV disease
risk with vitamin D supplementation at moderate to high
doses (approximately 1,000 IU daily) (59).
Vitamin D and End-Stage Renal Disease
Patients with advanced CKD are known to have markedly
increased CV disease risk and have more vitamin D defi-
ciency (60,61). Patients with CKD are at high risk of
25(OH)D deficiency, and unlike non-CKD patients who
are able to more tightly regulate 1,25(OH)2D within the
Figure 2 Impact of Vitamin D and Hypertension in the Framingh
Kaplan-Meier curves showing the crude cumulative probability of first cardiovascula
with a 25-hydroxyvitamin D (25[OH]D) level 15 ng/ml is represented by blue line
CVD  cardiovascular disease. Reproduced with permission from Wang et al. (52)
Figure 3 Impact of Vitamin D on
Mortality in the NHANES III Study
Restricted cubic spline showing the fully adjusted associations between serum
25-hydroxyvitamin D (25[OH]D) levels and all-cause mortality in 13,331 partici-
pants of the Third National Health and Nutrition Examination Survey. CI  con-
fidence interval. Reproduced with permission from Melamed et al. (53).ormal range, CKD patients also have profound reductions
n 1,25(OH)2D. In a study of 825 consecutive U.S. hemo-
ialysis patients, 78% were found to have vitamin D
eficiency and 18% were considered to be severely deficient
61). In another cohort of 175 consecutive hemodialysis
atients who died within 90 days and 750 patients who
urvived, low vitamin D levels were associated with in-
reased mortality; compared to patients with the highest
5(OH)D or 1,25(OH)2D levels who received vitamin D
therapy, untreated deficient patients were at significantly
increased risk for early mortality (Fig. 7) (61).
In a large study of 51,000 end-stage CKD patients
who survived for at least 90 days after initiation of
hemodialysis, 2-year survival was assessed. Analyzing
13,864 who died and 37,173 who survived, 2-year mor-
tality was more than doubled among those who did not
receive injectable vitamin D therapy compared to those
who did. In multivariate analysis, injectable vitamin D
therapy was associated with an independent 20% reduc-
tion in overall mortality (60). Other observational studies
of patients with CKD and hyperparathyroidism found
that oral administration of 1,25(OH)2D3 (also known as
activated vitamin D or calcitriol) is associated with
improved survival (62). Thus far, vitamin D analogs given
to hemodialysis patients have been shown to improve
survival (63), including in a recent meta-analysis of 5
prospective studies (59).
Vitamin D Supplementation
Typically, nearly 95% of the body’s requirements for
vitamin D is derived from cutaneous synthesis from sun
exposure, with the remainder ingested from dietary
tudy
ts in participants (A) with hypertension and (B) without hypertension. The group
reas the group with a 25(OH)D level 15 ng/ml is represented by red lines.am S
r even
s, whe
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(65). Regarding vitamin D intake, the committee assumed
minimal sun exposure, and it determined that North Amer-
icans need on average 400 IU of vitamin D daily; people 71
years old and older may require as much as 800 IU per day.
Studies indicate, however, that the average U.S. adult
consumes only approximately 230 IU of vitamin D daily
(66). The IOM committee found that the evidence sup-
ported a role of vitamin D for bone health, but did not
Figure 4 Vitamin D and All-Cause and CV Mortality
Kaplan-Meier plots of (A) all-cause and (B) cardiovascular (CV) mortality in the 25
and Q4 (red lines). Log-rank test indicated a significant difference across all 25-hy
tive coronary angiographic patients. Reproduced with permission from Dobnig et a
Figure 5 Vitamin D and Survival in the Intermountain Study
Kaplan-Meier survival curves according to baseline vitamin D level: 30 ng/ml
(orange line), 16 to 30 ng/ml (green line), and 15 ng/ml (purple line). Sur-
vival differed significantly by initial vitamin D level (log-rank p 0.0001). Repro-
duced with permission from Anderson et al. (55).obelieve that the current level of evidence was sufficient for
other health conditions, including for the prevention and
treatment of CV diseases (65).
However, experts in this field have suggested that to
satisfy the body’s need for most people, vitamin D intake in
the range of 800 to 2,000 IU daily may be needed, doses that
are quite difficult to obtain without routine supplementa-
tion, particularly in areas with extreme winter climates and
higher latitudes (67). It should be recognized that an axiom
of many essential nutrients, including in all likelihood
vitamin D, is that repleting a deficiency predictably confers
powerful benefits, whereas supplementing a “normal” level
to supraphysiologic ranges results in neutral to even poten-
tially harmful effects. The U.S. Food and Drug Adminis-
tration noted that a dose of 2,000 IU daily has been
recognized to be safe (1), A recent review, however, con-
sidered that the safe upper level of vitamin D may be 10,000
IU daily (a dosage above this may increase the risk of renal
stones, especially in patients with severe CKD and/or
absorptive hypercalciuria) (68,69). However, the IOM has
recently suggested a new tolerable upper intake level of only
4,000 IU of vitamin D daily for the general adult population
(65) because of concern about potential toxicity at higher
levels of 25(OH)D (3,7,52,53,59,65).
Sunlight provides the most potent source of vitamin D,
with approximately 3,000 IU vitamin D3 for 5 to 10 min of
id-day, mid-year exposure of arms and legs for a light-skin
aucasian (4). Another potent source is the prescription of
ral supplements of 50,000 IU of either D2 or D3 every 2
eeks (1,4). Among standard dietary sources of vitamin D,
xyvitamin D quartiles (Q): Q1 (blue lines), Q2 (green lines), Q3 (orange lines),
itamin D quartiles (p  0.001). This analysis was performed on 3,258 consecu-
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October 4, 2011:1547–56 Vitamin D and Cardiovascular Diseaseto 1,000 IU per 3.5 oz serving, whereas orange juice or milk
fortified with vitamin D contains about 100 IU per serving
(1,4,70). Each 100 IU of vitamin D ingested daily produces
about 1 ng/ml increase in 25(OH)D levels (71,72). Gener-
ally, oral supplementation of either D2 or D3 increases levels
f vitamin D reasonably well (73). However, increases in
5(OH)D levels seem to persist longer after a bolus of D3
than with D2, so generally, D3 is considered to be more
otent (74). For patients with vitamin D deficiency, vitamin
2 or D3 should be started with boluses of 50,000 IU once
or twice weekly for 2 to 3 months. From a practical
standpoint, although vitamin D3 is more potent, it is not
readily available; therefore, almost all of the vitamin D
prescribed is done so in the vitamin D2 form. After this
repletion phase, maintenance therapy can be continued by
routine sunlight exposure or by prescribing vitamin D
supplements, 800 to 2,000 IU vitamin D3 daily or 50,000
U of either D2 or D3 every 2 weeks (1,4,72).
itamin D and CV Disease: Is the Hype Merited?
he substantial data discussed in the preceding text suggest
very high prevalence of vitamin D deficiency, and numer-
us studies suggest that low levels of vitamin D are
Figure 6 Vitamin D Supplementation and Mortality
Meta-analysis of data on all-cause mortality in 18 randomized controlled trials with
Adapted with permission from Autier et al. (58).ssociated with more CV disease events, which seem to be teduced by vitamin D supplementation. Nevertheless, there
ontinues to be considerable debate regarding the value of
outine vitamin D screening and supplementation for CV
isease prevention. Also, optimal levels of vitamin D have
ot been adequately established.
During recent decades, other nutrients have been associ-
ted with CV diseases, including vitamins E and C, beta
arotene, and folic acid to reduce levels of homocysteine.
lthough all of these presented with considerable promise,
one has stood the test of time or the rigors of randomized
ontrolled trials. Conversely, omega-3 fatty acids have also
een associated with CV disease protection, and that has
een substantiated by randomized controlled trials, espe-
ially of CHD and heart failure (75,76). Regarding vitamin D,
he question remains whether the hype regarding this
itamin/hormone will stand the test of time and pass the
igors of randomized controlled trials. Will vitamin D be
nother vitamin E, C, or folic acid, or will the results be
ore similar to those with omega-3 fatty acids (or better)?
lthough we agree with the recent editorial that the current
vidence “falls short” of providing definitive recommenda-
ions (77) and even a very recent meta-analysis of 51 studies
ound that the effects of vitamin D were nonsignificant on
in D. CI  confidence interval; SRR  summary relative risk.vitamhe endpoints of death, myocardial infarction, and stroke
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likely outweigh the risks.
A major double-blind randomized placebo-controlled
trial (VITAL [VITamin D and OmegA-3 TriaL]) spon-
sored by the National Institutes of Health and run by
Harvard Medical School and the Brigham and Women’s
Hospital in Boston, Massachusetts, is under way to assess
the impact of 2,000 IU vitamin D3 and/or omega-3 fatty
cids (Omacor, Pronova, Norway; fish oil, 1 g) on heart
isease, stroke, and cancer in 20,000 men and women in the
.S. Before enrollment has even been completed, this study
otentially has the limitations that baseline vitamin D status
s not being assessed in all patients (but nearly 80% or
6,000 will have baseline 25[OH]D assessments), the trial
Figure 7 Vitamin D Levels and Supplementation in Hemodialysi
Multivariate-adjusted odds ratios (ORs) of 90-day all-cause and cardiovascular (CV
received treatment with active vitamin D (orange bars) or no active vitamin D (yel
CV mortality; (C) 1,25-dihydroxyvitamin D (1,25[OH2]D) and all-cause mortality; an
who were treated with active vitamin D and had 25(OH)D levels 30 ng/ml or 1,2
yses, n  719. *p  0.05 for the comparison of the individual vitamin D level an
permission from Wolf et al. (61).ould attract healthier participants with higher levels of iitamin D at baseline compared to the general population
although a fairly representative U.S. population, including
5% African Americans, with ethnic/racial and geographic
iversity is being recruited), and also at least some people
ith very severe deficiency may not be “normalized” by these
oses (but on-treatment 25[OH]D levels will be tested in
,000 participants and, as reviewed above, we currently do
ot know what true “normalization” represents which may
e partly answered by this trial). Also, as would be the case
n every vitamin D study in the past and future, it is not
ossible to have a placebo group with no vitamin D
xposure, since even the nonsupplemented group can po-
entially obtain large amounts of vitamin D naturally from
kin synthesis after UVB exposure (which should be similar
lity for hemodialysis patients according to vitamin D levels and whether patients
rs). (A) 25-hydroxyvitamin D (25[OH]D) and all-cause mortality; (B) 25(OH)D and
,25-dihydroxyvitamin D and CV mortality. The reference groups (R) were subjects
)D levels 13 pg/ml. For 25(OH)D analyses, n  984; and for 1,25(OH2)D anal-
in D treatment groups with the corresponding referent groups. Reproduced withs
) morta
low ba
d (D) 1
5(OH2
d vitamn the control and vitamin D groups). Therefore, consider-
1555JACC Vol. 58, No. 15, 2011 Lavie et al.
October 4, 2011:1547–56 Vitamin D and Cardiovascular Diseaseing the large number in the population with suboptimal
vitamin D levels and the overall strengths of this trial, this
study should provide very important information for both
CV disease and cancer prevention.
Conclusions
Considerable evidence indicates that vitamin D deficiency is
extremely prevalent and associated with CV disease risk
factors (hypertension, T2DM/MetS, and inflammation)
and is associated with increased CV disease events, CV, and
all-cause mortality. Vitamin D deficiency can be prevented
and corrected easily by sunlight and/or vitamin D supple-
mentation. Although assessment of 25(OH)D levels is
reasonable for many adults, especially those with CV disease
or high CV risk, and treatment can easily be accomplished,
definitive randomized controlled trials are needed to deter-
mine whether vitamin D therapy will live up to its hype.
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